G12.0 Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
G12.1 Other inherited spinal muscular atrophy
G12.2 Motor neuron disease
G12.20 Motor neuron disease, unspecified
G12.21 Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS)

Also known as Lou Gehrig’s Disease, ALS is caused by the degeneration and death of motor neurons in the spinal cord and brain.

G12.22 Progressive bulbar palsy
G12.29 Other motor neuron disease
Primary lateral sclerosis

G12.8 Other spinal muscular atrophies and related syndromes
G12.9 Spinal muscular atrophy, unspecified

G13.0 Paraneoplastic neuromyopathy and neuropathy
Carcinomatous neuromyopathy
Sensory paraneoplastic neuropathy [Denny Brown]

G13.1 Other systemic atrophy primarily affecting central nervous system in neoplastic disease
Paraneoplastic limbic encephalopathy

G13.2 Systemic atrophy primarily affecting the central nervous system in myxedema

G13.8 Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere
Code first underlying disease

G14 Postpolio syndrome

EXTRAPYRAMIDAL AND MOVEMENT DISORDERS (G20-G26)

G20 Parkinson’s disease
Hemiparkinsonism
Idiopathic Parkinsonism or Parkinson’s disease
Paralysis agitans
Parkinsonism or Parkinson’s disease NOS
Primary Parkinsonism or Parkinson’s disease

Excludes 1
Armenia with Parkinsonism (G31.83)

Use this code for true muscle weakness as a result of musculoskeletal disorders, neuromuscular disease, or degenerative disease. Muscle group measurements are not required but measurable muscle weakness must be documented.

When a patient is reported to have Parkinson’s disease with related dementia, assign G20 followed by a code from category F02.8-, Dementia in diseases classified elsewhere. The physician must report the dementia as related to the Parkinson’s disease in order to code the dementia as a manifestation.

G21 Secondary parkinsonism

Excludes 1
Armenia with Parkinsonism (G31.83)
Huntington’s disease (G10)
Shy-Drager syndrome (G90.3)
Parkinsonism (G21.09)

Use additional code for adverse effect, if applicable, to identify drug

Malignant neuroleptic syndrome

Use additional code for adverse effect, if applicable, to identify drug

Use additional code for adverse effect, if applicable, to identify drug

Neuroleptic induced parkinsonism (G21.11)

G21.1 Other drug-induced secondary parkinsonism
Neuroleptic induced parkinsonism

Use additional code for adverse effect, if applicable, to identify drug

G21.19 Other drug induced secondary parkinsonism

Use additional code for adverse effect, if applicable, to identify drug

G21.2 Secondary parkinsonism due to other diseases classified elsewhere
Code first (T51-T65) to identify external agent

G21.3 Postencephalitic parkinsonism
G21.4 Vascular parkinsonism
G21.8 Other secondary parkinsonism
G21.9 Secondary parkinsonism, unspecified

G23 Other degenerative diseases of basal ganglia

Excludes 1
Multi-system degeneration of the autonomic nervous system (G91.3)

G23.0 Hallervorden-Spatz disease
Pigmentary palidal degeneration

G23.1 Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
Progressive supranuclear palsy

G23.2 Striatonigral degeneration

G23.3 Other specified degenerative diseases of basal ganglia
Calcification of basal ganglia

G23.9 Degenerative disease of basal ganglia, unspecified

G24 Dystonia

Excludes 2
Dystonia with athetoid cerebral palsy (G88.3)

G24.0 Drug induced dystonia
Use additional code for adverse effect, if applicable, to identify drug

G24.01 Drug induced subacute dystonia
Drug induced blepharospasm
Drug induced oral facial dystonia
Neuroleptic induced tardive dystonia
Tardive dystonia

Use additional code for adverse effect, if applicable, to identify drug

G24.02 Drug induced acute dystonia
Acute dystonic reaction to drugs